bioecon Member area
Technology · Health & biomedicine / Therapeutics & platforms

Biologics

Biologics — monoclonal antibodies, ADCs, CAR-T and gene therapy — are the largest and fastest-growing drug class, built on a reproducible cell-line platform at 2–10 g/L titers.

Maturity 6/9 Risk: low Pharma & biologics US · CN · EU Science: why it works → verified 2026-06-18 · 0 Sources (0 independent)

1 · What it gives

Biologics are drugs produced by living systems: monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fragment and bispecific antibodies, and advanced ATMPs (CAR-T, gene therapy). It is the largest drug class: a $400B+ global market, and biologics are >60% of big-pharma pipelines. mAb production in CHO cell lines reaches 2–10 g/L titers in fed-batch, and the platform (cell line → bioreactor → purification) is reproducible across molecules. ADCs and CAR-T extend the platform into targeted oncology.

Key directions of biologics:

  1. Monoclonal antibodies (Monoclonal Antibodies): blockers (Humira, Keytruda), bispecifics.
  2. Antibody-drug conjugates (Antibody-Drug Conjugates): Enhertu; the Pfizer–Seagen $43B deal.
  3. CAR-T and cell therapy (CAR-T & Cell Therapy): Kymriah, Yescarta; ~$400k per course.
  4. Gene therapy (Gene Therapy): Zolgensma, Luxturna — single-dose treatment of inherited disease.

Sectoral value chain#

[cell line] ──> [upstream] ──> [purification] ──> [formulation]
                    │
              (CHO, 2–10 g/L titer)
                    │
                    ▼
[drug product] <─── [fill-finish] <─────┘

Value chain levels#

LevelDescriptionKey inputs/outputs
Cell Line Developmentstable CHO line with the target transgeneIn: vector, cells. Out: MCB/WCB.
Upstream (Bioreactor)fed-batch/perfusion in bioreactorsIn: media, feed, gases. Out: supernatant.
Harvest & Clarificationcell separation, depth filtrationIn: supernatant. Out: liquor.
Downstream PurificationProtein A + ion-exchange chromatography, viral inactivationIn: liquor. Out: pure mAb.
Formulation (UF/DF)ultrafiltration/diafiltration, standardizationIn: pure mAb. Out: formulation.
Aseptic Fill-Finishsterile fill, lyophilisation, labellingIn: formulation. Out: drug product (vial/syringe).

Cross-cutting technologies of the sector:

  • CHO platform (CHO Platform): 2–10 g/L titers, reproducible cell line across molecules.
  • Single-use bioprocess (Single-Use Bioprocessing): disposable bags/bioreactors for flexibility.
  • High-throughput analytics (High-Throughput Analytics): PAT, mass spectrometry, charge profiling.

2 · What it replaces 0 · matched by industry

No graded substitution linked yet.

3 · How to implement 6 steps

  1. 1
    Cell lineStrains & cell lines
    A stable CHO line with the target transgene is cloned and banked (MCB/WCB).
    Who can do this step matched automatically
    CHITOSE Japan
    industrial scale
    “STABLE CELL LINE DEVELOPMENT SERVICE”
    Tsingke Biotechnology China
    “Tsingke Biotech is a leader in synthetic biology, committed to building a world-class gene factory.”
    ToolGen (KOSDAQ) South Korea
    “Toolgen is committed to conducting research for revamping genome editing technology and thus developing not only therapeutics for humans but plants and animals of which the genetic …”
    Fermelanta Japan
    3,000 L pilot scale
    “is a Japan-based biomanufacturing/synthetic biology startup engineering fast-growing E.”
    Sartorius Germany
    industrial scale
    “[ Cell Culture Media, Cell Lines & Buffers”
    CRUST Group Singapore
    50,000L
    “2026-09-12 [AI and CRISPR combine to tackle crop breeding’s next challenge - AG Life Media — The article discusses a partnership between DNA Harvest Partners and ToolGen to …”
  2. 2
    Upstream bioreactorFermentation & cultivation
    Fed-batch or perfusion in bioreactors reaches 2–10 g/L titer under PAT control.
    Who can do this step matched automatically
    Ajinomoto Japan
    ✓ GMP industrial scale
    “It specializes in amino acid fermentation technology, applying it to seasonings, processed foods, frozen foods, and healthcare solutions.”
    CHITOSE Japan
    industrial scale
    “AI x BIOMANUFACTURING”
    Loopworm India
    ✓ GMP 6,000 tonnes/year industrial scale
    “At Loopworm, we are building the future of sustainable biomanufacturing.”
    Tsingke Biotechnology China
    “Their platform supports large libraries (up to ~1,500 candidates/day) with diverse expression systems and rapid gene-to-antibody delivery, backed by ISO-certified facilities and …”
    PBS Biotech United States
    ✓ GMP industrial scale
    “PBS Biotech is advancing the future of cell therapy manufacturing through innovative, single-use bioreactor solutions designed specifically for shear-sensitive cell cultures.”
  3. 3
    Harvest & clarificationPurification & downstream
    Centrifugation and depth filtration remove cells, yielding clarified liquor.
    Who can do this step matched automatically
    HLB Genex (ex-GenoFocus) South Korea
    industrial scale
    “With fungal and bacterial secretion systems, we custom produce the evolved enzyme products in large-scale fermentation and downstream processes.”
    Algal Bio Japan
    industrial scale
    “・Equipped with comprehensive downstream processing capabilities (Concentration, sterilization, and drying)”
    Space F South Korea
    “2026-07-12 [Korea's next drug lab is in orbit - The Korea Herald — Space LiinTech is advancing Korea’s foray into space-based drug research with autonomous microgravity platforms …”
    Alfa Laval Sweden
    “Here we compare the three most common options: centrifugation, filtration and coalescence.”
    GEA Group Germany
    “[Evaporation & Crystallization Systems”
    Pivot Bio United States
    “Commercial AgronomySalesAccountingCorp FinanceITProduct ManufacturingDownstream Process DevelopmentDEPARTMENT”
  4. 4
    Chromatography & viral safetyPurification & downstream
    Protein A → ion-exchange chromatography; viral inactivation and filtration (ICH Q5A).
    Who can do this step matched automatically
    HLB Genex (ex-GenoFocus) South Korea
    industrial scale
    “With fungal and bacterial secretion systems, we custom produce the evolved enzyme products in large-scale fermentation and downstream processes.”
    Algal Bio Japan
    industrial scale
    “・Equipped with comprehensive downstream processing capabilities (Concentration, sterilization, and drying)”
    Space F South Korea
    “2026-07-12 [Korea's next drug lab is in orbit - The Korea Herald — Space LiinTech is advancing Korea’s foray into space-based drug research with autonomous microgravity platforms …”
    Alfa Laval Sweden
    “Here we compare the three most common options: centrifugation, filtration and coalescence.”
    GEA Group Germany
    “[Evaporation & Crystallization Systems”
    Pivot Bio United States
    “Commercial AgronomySalesAccountingCorp FinanceITProduct ManufacturingDownstream Process DevelopmentDEPARTMENT”
  5. 5
    UF/DF & formulationFormulation & blending
    Ultrafiltration/diafiltration concentrates the mAb and transfers it into formulation.
  6. 6
    Fill-finish & QCPackaging & fill-finishTesting & analytics
    Sterile filling, lyophilisation (as needed), serialisation and batch release.
    Who can do this step matched automatically
    Pakka (ex-Yash Pakka) India
    1940 MT per annum industrial scale
    “Pakka Limited (located in Ayodhya, India) provides regenerative packaging solutions for food products.”
    Alterpacks Singapore
    “[Alterpacks - New Materials Solutions — AlterPacks is a Singapore-based startup that develops sustainable packaging materials sourced from agricultural by-products.”
    TÜBİTAK Marmara Research Center Turkey
    “More than 1,500 researchers work in 15 different research institutes of TÜBİTAK where contract research as well as targeted and nation-wide research is conducted.”
    Turion Labs Singapore
    “Turion Labs is a Singapore-headquartered biotech innovation platform that provides shared laboratory infrastructure, contract research organization (CRO) services, and regulatory …”

4 · Who delivers

Matched suppliers (matched automatically)

GOOD Meat (Eat Just)SingaporeProduceractive
Tsingke BiotechnologyChinaProduceractive
SartoriusGermanyProduceractive
CHITOSEJapanResearch / RTOactive
HipraSpainProduceractive

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
Roche🇨🇭 SwitzerlandHerceptin, Avastin, RituxanCHO platform, GenentechCommercial
Novartis🇨🇭 SwitzerlandKymriah (CAR-T), Cosentyxfirst approved CAR-TCommercial
Sanofi🇫🇷 FranceDupixent, Sarclisabispecific antibodiesCommercial
AbbVie🇺🇸 USAHumira, Skyriziimmunology mAbsCommercial
Amgen🇺🇸 USAEnbrel, biosimilarslarge-scale platformCommercial
WuXi Biologics🇨🇳 Chinabiologics CRDMObioproduction capacityCommercial

5 · Rules & route to market

United States

The US is the largest biologics market and leads on ATMP M&A and VC.

MAb & ADC leadership, M&A consolidation, FDA#

  • AbbVie / Amgen: Humira (peak >$20B/year) and Enbrel; bispecifics.
  • Pfizer → Seagen ($43B): consolidating ADC leadership.
  • FDA: expedited pathways (Breakthrough, RMAT) for CAR-T and gene therapy.
European Union

The EU is home to the largest biopharma giants and bioproduction-sovereignty programs.

Roche/Novartis/Sanofi, France Bioproduction 2030, EMA ATMP#

  • Roche/Novartis/Sanofi: Herceptin, Kymriah, Dupixent — mAb/CAR-T/antibody flagships.
  • France “Bioproduction 2030”: mAb production localisation, flexible iFab mini-plants.
  • EMA ATMP: strict regulation of CAR-T and gene therapy.
China

China is rapidly scaling biomanufacturing capacity and a biosimilar portfolio.

WuXi & biosimilar scale, NMPA pathway, capacity build-out#

  • WuXi Biologics: the largest biologics CRDMO platform.
  • Biosimilars: mass production of domestic mAb biosimilars.
  • NMPA: accelerated approval for strategically important molecules.

6 · Money: tenders & grants

GrantBlueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the …
National Institutes of Health · United States
Aug 18, 2027
306 days

Public R&D projects 2

Publicly funded research projects (US NSF, and EU, UK and other funders via OpenAIRE) whose title names this technology — matched by title, not reviewed; amounts as awarded, in the funder's currency. all funded projects →

2027EPSCoR Graduate Fellowship Program (EGFP): Site in Biologics Process Discovery, Development and Biomanufacturing
NSF · 2535438
1,908,000 USD
2026I-Corps: Translation potential of an artificial intelligence and hybrid platform for designing disease-specific biologics and molecular …
NSF · 2628400
50,000 USD

7 · Tech stack & innovations

The stack rests on the cell line, the bioreactor and deep purification.

  1. CHO platform (CHO Cell-Line Platform):
    • fed-batch at 2–10 g/L titer; reproducible genetics across molecules.
    • case: Roche/Genentech — the benchmark large-scale mAb platform.
  2. Single-use bioprocess (Single-Use Bioprocessing):
    • disposable bioreactors and bags cut capex and cross-contamination.
  3. ADC conjugation (ADC Conjugation):
    • linker-payload chemistry for targeted cytotoxic delivery to tumours (Enhertu).

Sources 0 · 0 independent · 0 producer sites